KPT185-trans isomer (which has ∼100 fold less XPO1 inhibition activity as the cis-isomer), showed much less toxicity when it was tested using Jurkat cells and one of primary canine DLBCL samples (IC50 were >1000 nM in both tumor cells). This evidence concerns the gene XPO1 and neoplasm.